Possible carcinogenic properties of a new chromogen, dicarboxydine (gamma,gamma'-3,3'-benzidine dioxydibutyric acid), tested in rats and mice.
The carcinogenic properties of gamma,gamma'-3,3'-benzidine dioxydibutyric acid [dicarboxydine (DCD)] were studied in 208 rats and 127 mice by either sc administration or by feeding of the compound for 24 months. Tumors developed in 21 of the 99 DCD-treated rats that survived to the time of the first tumor appearance. In DCD-treated rats, tumors different from those in the controls were noted in the bladder, prostate gland, uterine body, and other organs, but in single cases only. Four rats had sarcomas at the site of DCD injection. DCD had no carcinogenic effect in mice. In view of the longer times of tumor induction and multiple tumor development only in rats given sc injections of DCD, the conclusion was reached that DCD is of dubious or negative carcinogenicity.
D015100:3,3'-Diaminobenzidine / Q000031:analogs & derivatives / Q000633:toxicity*; D000818:Animals; D001560:Benzidines / Q000633:toxicity*; D002087:Butyrates / Q000633:toxicity; D002273:Carcinogens; D004353:Drug Evaluation, Preclinical; D005260:Female; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D051381:Rats
D001560:Benzidines; D002087:Butyrates; D002273:Carcinogens; C018917:dicarboxydine; D015100:3,3'-Diaminobenzidine